Table 4.
Diversity of iKIR2D/HLA-C licensing interactions in controls and myeloma patients.
| Frequency, n (%) |
Multivariate logistic regression |
||||
|---|---|---|---|---|---|
| Combinations of conventional iKIR2D/HLA-C licensing interactions1 | Controls (n=286 ) | SMM+MM (n=78 ) | OR | Analysis 95%CI | p |
| No iKIR2D/HLA-C interactions2 | 1 (0.35%) | 2 (2.56%) | 15.014 | 1.171–195.55 | 0.037 |
| Single-KIR2DL3+/C1+ | 31 (10.84%) | 16 (20.51%) | 2.795 | 1.183–6.603 | 0.019 |
| Single-KIR2DL2+/C1+ | 14 (4.9%) | 10 (12.82%) | 5.182 | 1.795–14.960 | 0.002 |
| Single-KIR2DL1+/C2+ | 53 (18.5%) | 9 (11.54%) | 1.089 | 0.426–2.728 | 0.858 |
| Double-KIR2DL2+L3+/C1+ | 51 (17.83%) | 6 (7.69%) | 0.727 | 0.255–2.068 | 0.550 |
| Double-KIR2DL1+L3+/C2+C1+ | 53 (18.53%) | 18 (23.08%) | 1.936 | 0.855–4.382 | 0.113 |
| Double-KIR2DL1+L2+/C2+C1+ | 13 (4.56%) | 5 (6.41%) | 2.335 | 0.703–7.758 | 0.166 |
| Triple-KIR2DL1+L2+L3+/C2+C1+3 | 70 (24.48%) | 12 (15.38%) | 1.0 | N.A. | 0.004 |
OR, odd ratio; 95%CI, 95% confidence interval.
1
Ordered following previously described (conventional) KIR2D-ligand affinity hierarchy: KIR2DL3/C1 < KIR2DL2/C1 < KIR2DL1/C2.37
2
Patients with no conventional iKIR2D/HLA-C licensing interactions (but with the non-conventional KIR2DL2/C2 interaction).
3
Reference category. N.A.: no applicable.